Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Rating of “Buy” from Analysts

Avalyn Pharma Inc. (NASDAQ:AVLN) has earned a consensus rating of “Buy” from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, two have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $59.00.

A number of research firms recently weighed in on AVLN. Morgan Stanley initiated coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 price objective for the company. Zacks Research upgraded Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Evercore initiated coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price objective for the company. Finally, Jefferies Financial Group started coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $52.00 price objective on the stock.

Avalyn Pharma Stock Up 10.2%

Shares of NASDAQ:AVLN opened at $28.30 on Friday. The firm has a market cap of $1.25 billion and a P/E ratio of -1.30. Avalyn Pharma has a 12-month low of $24.15 and a 12-month high of $33.32. The business’s 50-day simple moving average is $28.88.

Avalyn Pharma (NASDAQ:AVLN) last announced its earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share for the quarter, missing the consensus estimate of ($16.38) by ($5.45).

Insider Transactions at Avalyn Pharma

In other Avalyn Pharma news, Director Jill Carroll purchased 277,778 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The shares were acquired at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the transaction, the director owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This trade represents a 14.55% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the stock in a transaction dated Friday, May 1st. The stock was acquired at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the purchase, the insider owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 34.06% increase in their position. The SEC filing for this purchase provides additional information.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.